tiprankstipranks
Trending News
More News >
Boundless Bio Inc. (BOLD)
NASDAQ:BOLD
US Market
Advertisement

Boundless Bio Inc. (BOLD) Drug Pipeline

Compare
36 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Bbi-825
Solid Tumor
Phase I
Completed
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
Feb 26, 2024
Erlotinib, Bbi-825, Bbi-355, Futibatinib
Small Cell Lung Cancer, Pancreatic Cancer Metastatic, Triple Negative Breast Cancer (Tnbc), Er+ Breast Cancer, Cervical Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma (Cscc), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head And Neck (Hnscc), Leiomyosarcoma (Lms), Undifferentiated Pleomorphic Sarcoma (Ups)
Phase I
Recruiting
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Mar 27, 2023

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Boundless Bio Inc. (BOLD) have in its pipeline
      BOLD is currently developing the following drugs: Bbi-825, Erlotinib, Bbi-825, Bbi-355, Futibatinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis